Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Overview Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership

Ticker	Company	Country	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
FONR	FONAR CORP	United States	$118.18M	6,710,807	47.70%	3.51%
ICLR	ICON PLC	Ireland	$26.06B	82,683,805	95.42%	0.00%
STRR	STAR EQUITY HOLDINGS INC	United States	$14.58M	15,848,202	3.66%	96.34%	Net Buying	Net Selling
RVTY	REVVITY INC	United States	$12.70B	123,529,821	86.51%	2.55%	Net Buying	Net Selling
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	United States	$12.08B	51,349,770	96.79%	3.21%	Net Selling	Net Selling
NEOG	NEOGEN CORP	United States	$2.63B	216,607,746	98.55%	1.45%	Net Buying	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	United States	$218.93B	381,716,323	89.16%	0.88%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	United States	$39.38B	82,587,328	88.25%	1.69%	Net Buying	Net Selling
ENZ	ENZO BIOCHEM INC	United States	$54.81M	51,225,734	31.93%	48.12%	Net Selling
DGX	QUEST DIAGNOSTICS INC	United States	$15.07B	111,091,574	87.75%	1.76%	Net Selling	Net Selling
QGEN	QIAGEN NV	Netherlands	$9.53B	223,904,000	62.58%	0.00%
SHC	SOTERA HEALTH CO	United States	$3.20B	283,070,826	61.96%	38.04%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	United States	$41.21B	293,055,284	87.43%	1.18%	Net Buying	Net Selling
DHR	DANAHER CORP	United States	$183.25B	740,686,541	75.94%	24.06%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	United States	$12.42B	30,983,399	27.35%	72.65%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	United States	$643.07M	29,924,288	41.31%	58.69%	Net Selling	Net Selling
WAT	WATERS CORP	United States	$18.94B	59,202,626	92.46%	7.54%	Net Selling	Net Selling
LH	LABORATORY CORP OF AMERICA HOLDINGS	United States	$16.95B	84,293,628	95.55%	1.52%	Net Selling	Net Selling
SERA	SERA PROGNOSTICS INC	United States	$321.66M	32,425,661	34.04%	21.12%	Net Selling	Net Selling
PRE	PRENETICS GLOBAL LTD	Hong Kong	$70.55M	12,205,200	10.04%	0.00%
CSTL	CASTLE BIOSCIENCES INC	United States	$673.89M	27,607,183	84.19%	15.81%	Net Selling	Net Selling
IQV	IQVIA HOLDINGS INC	United States	$41.37B	182,200,000	53.95%	46.05%	Net Selling	Net Selling
PSNL	PERSONALIS INC	United States	$80.30M	50,503,889	43.52%	18.38%	Net Selling	Net Buying
PRPO	PRECIPIO INC	United States	$8.55M	1,430,292	0.61%	99.39%	Net Buying	Net Buying
NTRA	NATERA INC	United States	$11.74B	120,757,877	78.43%	21.57%	Net Selling	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	United States	$26.87B	21,478,705	94.58%	4.52%	Net Selling	Net Buying
DRIO	DARIOHEALTH CORP	Israel	$47.11M	29,442,532	29.42%	53.98%
OLK	OLINK HOLDING AB (PUBL)	Sweden	$2.88B	124,342,715	30.18%	0.00%
ACRS	ACLARIS THERAPEUTICS INC	United States	$92.91M	70,925,042	56.84%	43.16%	Net Selling	Net Selling
STIM	NEURONETICS INC	United States	$111.59M	29,756,053	50.13%	49.87%	Net Selling	Net Selling
DMTK	DERMTECH INC	United States	$21.71M	34,623,443	15.75%	77.74%	Net Selling	Net Selling
NEO	NEOGENOMICS INC	United States	$1.98B	127,711,930	72.39%	27.61%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	United States	$2.60B	58,225,999	88.25%	11.75%	Net Selling	Net Selling
EXAS	EXACT SCIENCES CORP	United States	$11.50B	181,530,967	88.62%	3.32%	Net Selling	Net Selling
OCX	ONCOCYTE CORP	United States	$22.92M	8,273,073	5.82%	94.18%	Net Buying	Net Buying
BNR	BURNING ROCK BIOTECH LTD	China	$83.28M	102,440,448	19.65%	0.00%
BGLC	BIONEXUS GENE LAB CORP	Malaysia	$10.51M	17,667,663	0.59%	97.91%
RDNT	RADNET INC	United States	$3.56B	68,475,443	64.36%	35.64%	Net Selling
APDN	APPLIED DNA SCIENCES INC	United States	$3.08M	848,935	11.48%	88.52%
LAB	STANDARD BIOTOOLS INC	United States	$719.49M	290,117,930	16.74%	33.34%	Net Buying	Net Buying
GH	GUARDANT HEALTH INC	United States	$2.32B	121,712,724	64.24%	35.76%	Net Buying	Net Buying
XGN	EXAGEN INC	United States	$23.79M	17,235,751	36.96%	63.04%	Net Selling	Net Selling
XWEL	XWELL INC	United States	$7.53M	4,183,435	1.65%	98.35%	Net Buying
BDSX	BIODESIX INC	United States	$147.35M	96,942,061	17.45%	72.27%	Net Buying	Net Selling
CDNA	CAREDX INC	United States	$527.11M	51,778,523	78.55%	21.45%	Net Selling	Net Selling
ME	23ANDME HOLDING CO	United States	$235.18M	482,916,636	27.87%	2.59%	Net Buying	Net Selling
CHEK	CHECK-CAP LTD	Israel	$12.89M	5,849,756	1.07%	0.00%
ULS	UL SOLUTIONS INC	United States	N/A	200,000,000	0.00%	0.30%	Net Selling	Net Selling
PRPH	PROPHASE LABS INC	United States	$96.36M	18,045,209	9.36%	57.17%
OPK	OPKO HEALTH INC	United States	$920.03M	696,991,667	17.43%	82.57%	Net Buying	Net Buying
AWH	ASPIRA WOMEN's HEALTH INC	United States	$39.62M	12,344,104	0.84%	99.16%	Net Buying
NDRA	ENDRA LIFE SCIENCES INC	United States	$3.56M	11,035,659	1.19%	8.73%	Net Buying
NOTV	INOTIV INC	United States	$123.02M	25,790,680	18.17%	43.71%	Net Buying
VNRX	VOLITIONRX LTD	United States	$63.93M	82,068,442	7.76%	40.12%	Net Buying	Net Selling
MDXH	MDXHEALTH SA	Belgium	$8.54M	27,288,093	11.79%	88.21%
MYGN	MYRIAD GENETICS INC	United States	$1.79B	89,874,886	92.31%	7.69%	Net Selling	Net Selling
GENE	GENETIC TECHNOLOGIES LTD	Australia	$549.39k	115,417,246	0.02%	0.00%
ISPC	ISPECIMEN INC	United States	$2.51M	9,087,467	4.31%	71.05%	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	United States	$22.68M	11,514,354	1.36%	37.32%	Net Buying	Net Buying
ILMN	ILLUMINA INC	United States	$18.95B	159,300,000	89.06%	1.97%	Net Selling	Net Buying
PMD	PSYCHEMEDICS CORP	United States	$14.59M	5,742,761	22.46%	50.15%	Net Selling
TRIB	TRINITY BIOTECH PLC	Ireland	$13.26M	153,310,284	3.93%	0.00%
MYNZ	MAINZ BIOMED NV	Germany	$15.66M	21,165,482	1.10%	0.00%
MMA	ALTA GLOBAL GROUP LTD	Australia	N/A	10,223,079	0.00%	0.00%
CNTG	CENTOGENE NV	Germany	$12.42M	27,595,835	9.75%	0.00%
TTOO	T2 BIOSYSTEMS INC	United States	$31.92M	8,792,950	0.51%	99.49%	Net Selling

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in May 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 6.6% over the past year, overperforming other diagnostic & research stocks by 5 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 47, which is 20 points higher than the diagnostic & research industry average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 66.03% over the past year, overperforming other diagnostic & research stocks by 64 percentage points.

Icon has an average 1 year price target of $344.38, an upside of 9.28% from Icon's current stock price of $315.14.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Icon, 75% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the third best diagnostic & research stock with a Zen Score of 46, which is 19 points higher than the diagnostic & research industry average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Star Equity Holdings has seen its stock return 8.24% over the past year, overperforming other diagnostic & research stocks by 7 percentage points.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.01%, which is 2 percentage points higher than the diagnostic & research industry average of 1.37%.

Qiagen Nv's dividend payout ratio of 87.2% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.12%, which is 1 percentage points higher than the diagnostic & research industry average of 1.37%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.2% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.43%, which is the same as the diagnostic & research industry average of 1.37%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 56.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 0.47% in the last day, and down -0.04% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 8.24% in the past year. It has overperformed other stocks in the diagnostic & research industry by 7 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -57.87% in the past year. It has underperformed other stocks in the diagnostic & research industry by -59 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 53 points higher than the diagnostic & research industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 6.6% in the past year. It has overperformed other stocks in the diagnostic & research industry by 5 percentage points.

Are diagnostic & research stocks a good buy now?

50% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 10.22% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 38.56x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.